Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

被引：23
|
作者：
Young, Kate [1 ]
Smyth, Elizabeth [1 ]
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp, Gastrointestinal Oncol Unit, Sutton SM2 5PT, Surrey, England
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2015年 / 8卷 / 06期
关键词：
angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2; RANDOMIZED PHASE-III; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; OPEN-LABEL; GROWTH; COMBINATION; PLUS; VEGF;
D O I：
10.1177/1756283X15592586
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
引用
收藏
页码：373 / 383
页数：11
相关论文
共 50 条
  • [1] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Buyukkaramikli, Nasuh C.
    Blommestein, Hedwig M.
    Riemsma, Rob
    Armstrong, Nigel
    Clay, Fiona J.
    Ross, Janine
    Worthy, Gill
    Severens, Johan
    Kleijnen, Jos
    Al, Maiwenn J.
    PHARMACOECONOMICS, 2017, 35 (12) : 1211 - 1221
  • [2] Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies
    Cappetta, Alessandro
    Lonardi, Sara
    Pastorelli, Davide
    Bergamo, Francesca
    Lombardi, Giuseppe
    Zagonel, Vittorina
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 81 (01) : 38 - 48
  • [3] The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma
    Garrido, Marcelo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (10) : 1005 - 1010
  • [4] European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions
    Pavlakis, Nick
    Tincknell, Gary
    Lim, Lisi Elizabeth
    Muro, Kei
    Obermannova, Radka
    Lorenzen, Sylvie
    Chua, Yu Jo
    Jackson, Chris
    Karapetis, Christos Stelios
    Price, Timothy
    Chantrill, Lorraine
    Segelov, Eva
    Lordick, Florian
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [5] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
    Wilke, Hansjochen
    Muro, Kei
    Van Cutsem, Eric
    Oh, Sang-Cheul
    Bodoky, Gyoergy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg
    Kim, Tae-You
    Cunningham, David
    Rougier, Philippe
    Komatsu, Yoshito
    Ajani, Jaffer
    Emig, Michael
    Carlesi, Roberto
    Ferry, David
    Chandrawansa, Kumari
    Schwartz, Jonathan D.
    Ohtsu, Atsushi
    LANCET ONCOLOGY, 2014, 15 (11) : 1224 - 1235
  • [6] Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
    Khan, Uqba
    Shah, Manish A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1135 - 1141
  • [7] Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
    Davidson, Michael
    Smyth, Elizabeth C.
    Cunningham, David
    ONCOTARGETS AND THERAPY, 2016, 9 : 4539 - 4548
  • [8] The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer
    Cartwright, Elizabeth
    Cunningham, David
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (12)
  • [9] Ramucirumab for gastric cancer
    Shitara, Kohei
    Ohtsu, Atsushi
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (02) : 133 - 139
  • [10] Gastric and gastro-oesophageal cancer therapy
    Das, P
    Ajani, JA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2805 - 2812
12345